Akeso Secures $250 Million USD for Global Drug Pipeline Expansion

Akeso Biopharma, a leading biopharmaceutical company, has successfully raised approximately $250 million USD through a share placement. This significant investment reflects the company's long-term investment value and its potential for global growth. The funds will be primarily allocated to accelerating the global clinical development of innovative drugs developed internally by Akeso, with a focus on its core products in both China and international markets.

Akeso's Founder, Chairwoman, President, and Chief Executive Officer, Dr. Xia Yu, expressed her enthusiasm about the efficient completion of this share placement. She emphasized that the success of this financing will bolster Akeso's global development strategy, particularly by accelerating multi-center international clinical trials led by the company. This initiative will enhance the global value exploration of Akeso's internally developed new drugs and further strengthen its competitiveness in the international market.

With this substantial investment, Akeso will prioritize the development of its core products, such as cadonilimab and ivonescimab, in both China and international markets. The company will also explore new therapeutic areas and modalities to maximize the clinical impact of its key offerings and establish a strong base for its medium to long-term global growth.

Akeso will leverage this funding to expedite its global expansion through strategic partnerships and collaborations. By working with international long-term and healthcare funds, the company aims to expedite international clinical trials for its pivotal products and enhance its global competitiveness in the pharmaceutical industry. This approach will enable Akeso to deliver superior clinical benefits to patients worldwide and solidify its position as a global leader in cancer immunotherapy bispecific antibodies.